AVXLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
ANAVEX LIFE SCIENCES CORP.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 28, 2026
$1.25−0.06 (-4.58%)
Close on Oct 19, 2026
- Market cap
- $116.12B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.73 (−86.08%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $116.12B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1032.70
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$13.02M
- EPS, diluted
- -$0.15
- Book value per share
- $0.00
- Diluted shares
- 92.90B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Operating income
-$17.37M
Net income
-$13.02M
EPS, diluted
-$0.15
Free cash flow
–
Reported periodTrailing twelve months